Daiana Giannini
Overview
Explore the profile of Daiana Giannini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petrelli F, Giannini D, Pucci C, Del Corso I, Rocchi V, Dolcher M, et al.
Int Arch Allergy Immunol
. 2022 Oct;
184(1):54-62.
PMID: 36265449
Introduction: Immediate and delayed hypersensitivity reactions (HSR) to COVID-19 vaccines are rare adverse events that need to be prevented, diagnosed, and managed in order to guarantee adherence to the vaccination...
2.
Calcinai L, Bonomini M, Leni G, Faccini A, Puxeddu I, Giannini D, et al.
Sci Rep
. 2022 Oct;
12(1):16902.
PMID: 36207409
The interest in agri-food residues and their valorization has grown considerably, and many of them are today considered to be valuable, under-exploited sources of different compounds and notably proteins. Despite...
3.
Petrelli F, Giannini D, Bilia S, Del Corso I, Rocchi V, Migliorini P, et al.
Front Allergy
. 2022 Aug;
3:952079.
PMID: 35935020
Urticarial vasculitis (UV) is a small-vessel leukocytoclastic vasculitis characterized by different clinical manifestations ranging from long-lasting urticarial lesions to severe and potentially life-threatening multi-organ involvement. Omalizumab (OMA), anti-IgE recombinant humanized...
4.
Ferri C, Raimondo V, Gragnani L, Giuggioli D, Dagna L, Tavoni A, et al.
Curr Pharm Des
. 2022 Jun;
28(24):2022-2028.
PMID: 35726427
Objective: Autoimmune systemic diseases (ASD) represent a predisposing condition to COVID-19. Our prospective, observational multicenter telephone survey study aimed to investigate the prevalence, prognostic factors, and outcomes of COVID-19 in...
5.
Ferri C, Giuggioli D, Raimondo V, LAndolina M, Dagna L, Tavoni A, et al.
Curr Pharm Des
. 2021 Sep;
27(41):4245-4252.
PMID: 34477509
Background: The Covid-19 pandemic may have a deleterious impact on patients with autoimmune systemic diseases (ASD) due to their deep immune-system alterations. Objective: This study aims to investigate the prevalence...
6.
Testa D, Calvacchi S, Petrelli F, Giannini D, Bilia S, Alunno A, et al.
Clin Exp Rheumatol
. 2021 May;
39(3):445-452.
PMID: 34018918
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterised by local and systemic inflammation where the close interaction between immune cells and soluble mediators leads to amplification and perpetuation of...
7.
Ferri C, Giuggioli D, Raimondo V, Dagna L, Riccieri V, Zanatta E, et al.
Lancet Rheumatol
. 2021 Feb;
3(3):e166-e168.
PMID: 33521657
No abstract available.
8.
Ferri C, Giuggioli D, Raimondo V, LAndolina M, Tavoni A, Cecchetti R, et al.
Clin Rheumatol
. 2020 Aug;
39(11):3195-3204.
PMID: 32852623
Introduction: Covid-19 infection poses a serious challenge for immune-compromised patients with inflammatory autoimmune systemic diseases. We investigated the clinical-epidemiological findings of 1641 autoimmune systemic disease Italian patients during the Covid-19...
9.
Bilia S, Giannini D, Rizzelli G, Tavoni A
Clin Exp Rheumatol
. 2020 May;
38(3):579.
PMID: 32456767
No abstract available.
10.
Papa N, Vitali C, Bilia S, Giannini D, Pignataro F, Minniti A, et al.
Clin Exp Rheumatol
. 2020 May;
38 Suppl 125(3):181-182.
PMID: 32452347
No abstract available.